Affimed (AFMD) said Monday that AFM28 showed "promising" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.
The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.
The company said AFM28 showed a "favorable" safety profile, with no signs of neurotoxicity or immune-related side effects seen.
Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.
Price: 2.27, Change: -0.06, Percent Change: -2.58
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。